Emergen logo.png
Lung Cancer Therapeutics Market Size Worth USD 57.69 Billion in 2032 | Emergen Research
January 04, 2024 07:45 ET | Emergen Research
Vancouver, Jan. 04, 2024 (GLOBE NEWSWIRE) -- The global lung cancer therapeutics market size was USD 28.00 Billion in 2022 and is expected to register a rapid revenue CAGR of 7.7% during the...
logo.png
Corbus Pharmaceuticals Provides Management Team Updates
March 28, 2019 08:05 ET | Corbus Pharmaceuticals Holdings, Inc.
Mark Tepper, Ph.D., transitions to role of external Senior Scientific Advisor Robert Discordia, Ph.D., role expanded to lead Chemistry, Manufacturing and Controls operationsSergei Atamas, M.D.,...
Nuvilex to Answer In
Nuvilex to Answer Increasing Calls for Better Pancreatic Cancer Treatment Without Gemcitabine
December 16, 2013 09:15 ET | Nuvilex, Inc.
NEW YORK, NY--(Marketwired - Dec 16, 2013) - Nuvilex, Inc. (OTCQB: NVLX) may be just what the National Cancer Institute (NCI) and a growing number of doctors ordered - the company's late stage...
FDA Approves ABRAXAN
FDA Approves ABRAXANE(R) for Pancreatic Cancer, Could Nuvilex's Treatment Be Next
September 09, 2013 08:30 ET | Nuvilex, Inc.
NEW YORK, NY--(Marketwired - Sep 9, 2013) - After presenting the results of its large scale Phase III clinical trial at the 2013 Gastrointestinal Cancers Symposium of the American Society of...
Stock Market Media G
Stock Market Media Group Issues Nuvilex, Inc. Road to Phase III Clinical Trials Report
August 15, 2013 08:30 ET | Nuvilex, Inc.
NEW YORK, NY--(Marketwired - Aug 15, 2013) - Stock Market Media Group, a research and content development investor relations firm, issued its Third Quarter Update and the first installment of its...